Assess the handoffs where product or presentation changes could create confusion. FDA has reported dosing errors involving compounded injectable semaglutide, including confusion among milligrams, millilitres and syringe units. It has separately raised concerns about inadequate refrigeration during shipment of injectable GLP-1 products. (fda.gov)
Answers stay in this session unless you choose to save. No account needed.
Evidence to attach: approved procedures, sample labels and instructions, escalation contacts and the walkthrough record.
If you score 0–1: close the clinical-handling gaps before implementation. Procurement should not invent dose conversions, treatment schedules or substitution instructions.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded